leukemia

Ovarian cancer could be next application for CAR T-cell therapyWhile CAR T-cell therapy has been proven to work for liquid—or blood—cancers, the challenge has been to apply this technology to solid tumors.
Personalized and costly, but new ALL treatment offers hopeA new customized therapy for acute lymphoblastic leukemia (ALL) offers high remission rates but at a substantial cost, and only at specialized cancer centers.
Four new treatments for acute myeloid leukemia to watchKey takeaways for healthcare executives from Bruno Medeiros, MD, associate professor of medicine (hematology) at the Stanford University Medical Center and director of Cancer Center Infusion Area Treatment Services at Stanford Cancer Center.
Four new treatments for acute myeloid leukemia to watchKey takeaways for healthcare executives from Bruno Medeiros, MD, associate professor of medicine (hematology) at the Stanford University Medical Center and director of Cancer Center Infusion Area Treatment Services at Stanford Cancer Center.
This is why you should be excited for upcoming cancer researchAcute myeloid leukemia experts share promising new developments on the oncology horizon.
FDA okays targeted leukemia treatmentFDA approved a targeted new drug to treat adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
FDA approves novel leukemia, hepatitis C drugsFDA approved the first treatment for patients with a certain type of acute myeloid leukemia, as well as 2 new drugs to treat hepatitis C.
FDA approves first targeted leukemia drug for certain patients, plus 2 moreLate last week, FDA approved a new drug to treat acute myeloid leukemia (AML), the first treatment for Batten disease, and expanded the use of a current drug to treat liver cancer.
Family history, genetics play growing role in leukemia screeningInherited susceptibilities to leukemias are becoming better understood and have important implications for screening, prevention, genetic counseling, and treatment.
Novel immunotherapies for leukemia could raise life-threatening syndromeNovel immunotherapy treatments are showing promise for patients with acute lymphoblastic leukemia (ALL), but they can trigger cytokine release syndrome.